Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD1 | P11586 | 2/20 | 0.86 |
| ▸ | DHFR | P00374 | 1/20 | 0.81 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.69 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | FPGS | Q05932 | 2/20 | 0.61 |
| ▸ | TYMS | P04818 | 1/20 | 0.58 |
| ▸ | ATIC | P31939 | 3/20 | 0.57 |
| ▸ | GART | P22102 | 6/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levomefolic Acid SCHEMBL30051011 | 1.00 | MTHFD1 (0.86) | MTHFD1DHFRSOSTMTHFD2LMNA | |
| Levomefolic Acid SCHEMBL2693607 | 1.00 | MTHFD1 (0.86) | MTHFD1DHFRSOSTMTHFD2LMNA | |
| Levomefolic Acid SCHEMBL31173596 | 1.00 | MTHFD1 (0.86) | MTHFD1DHFRSOSTMTHFD2LMNA | |
| Levomefolic Acid SCHEMBL7678398 | 1.00 | MTHFD1 (0.86) | MTHFD1DHFRSOSTMTHFD2LMNA | |
| Levomefolic Acid SCHEMBL79039 | 1.00 | MTHFD1 (0.86) | MTHFD1DHFRSOSTMTHFD2LMNA | |
| Levomefolic Acid SCHEMBL29616390 | 1.00 | MTHFD1 (0.86) | MTHFD1DHFRSOSTMTHFD2LMNA | |
| Levomefolic Acid SCHEMBL258787 | 1.00 | MTHFD1 (0.86) | MTHFD1DHFRSOSTMTHFD2LMNA | |
| Levomefolic Acid SCHEMBL1882912 | 1.00 | MTHFD1 (0.86) | MTHFD1DHFRSOSTMTHFD2LMNA | |
| Levomefolic Acid SCHEMBL4727836 | 1.00 | MTHFD1 (0.86) | MTHFD1DHFRSOSTMTHFD2LMNA | |
| Levomefolic Acid SCHEMBL30828726 | 1.00 | MTHFD1 (0.86) | MTHFD1DHFRSOSTMTHFD2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4395782-A1 | CONJUGATES, COMPOSITIONS, AND METHODS FOR REJUVENATION OF CAR T-CELLS | Purdue Research Foundation (US) | 2024-07-10 | — | — | EP | claimed |
| WO-2023034341-A1 | CONJUGATES, COMPOSITIONS, AND METHODS FOR REJUVENATION OF CAR T-CELLS | PURDUE RESEARCH FOUNDATION (US) | 2023-03-09 | — | — | WO | claimed |
| US-20260130873-A1 | COMPOSITIONS AND METHODS FOR TREATING HOMOCYSTINURIA AND OTHER CONDITIONS | THE REGENTS OF THE UNIV OF COLORADO A BODY CORPORATE (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260114488-A1 | COMPOSITIONS AND METHODS FOR PROMOTING DEVELOPMENT OF INFANT | BOBBIE BABY INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12465579-B2 | Compositions and methods for treating homocystinuria and other conditions | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-11-11 | — | — | US | disclosed |
| WO-2025132557-A1 | SOLID FORMULATIONS OF TETRAHYDROFOLATES | LESAFFRE ET COMPAGNIE (FR) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025125324-A1 | AAV-MEDIATED GENE THERAPY OF DISEASES CAUSED BY IMPAIRED FUNCTION OF GLDC | UCL BUSINESS LTD (GB) | 2025-06-19 | — | — | WO | disclosed |
| US-20250090609-A1 | COMPOSITIONS AND METHODS FOR PROMOTING DEVELOPMENT OF INFANT | JPMORGAN CHASE BANK, N.A. | 2025-03-20 | — | — | US | disclosed |
| US-20240285683-A1 | Compositions And Methods For Enhancing Immunotherapy | THE TRUSTEES OF PRINCETON UNIVERSITY | 2024-08-29 | — | — | US | disclosed |
| EP-4395782-A1 | CONJUGATES, COMPOSITIONS, AND METHODS FOR REJUVENATION OF CAR T-CELLS | Purdue Research Foundation (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4370105-A1 | USE OF METHANOL AND PRODRUGS THEREOF IN THERAPY | Ludwig Institute for Cancer Research Ltd (CH) | 2024-05-22 | — | — | EP | disclosed |
| CN-115605188-A | Compositions comprising methylfolic acid | 阿尔法西格玛有限公司（IT） | 2023-01-13 | — | — | CN | disclosed |
| EP-4103174-A1 | SMARTCORE COMPOSITIONS AND METHODS | NPI, LLC (US) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022241262-A2 | SMALL MOLECULE-BASED BI-SPECIFIC IMMUNE CELL TETHERS AND THEIR USE IN THE TREATMENT OF ENVELOPED VIRUS INFECTION | PURDUE RESEARCH FOUNDATION (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022167375-A1 | COMPOSITION AND METHOD FOR BIOFORTIFICATION OF FOOD PLANTS AND FOOD PLANTS THUS FORTIFIED. | FABBRICA COOPERATIVA PERFOSFATI CEREA S.C. (IT) | 2022-08-11 | — | — | WO | disclosed |
| WO-2022144804-A1 | METHOD FOR DETERMINING B VITAMINS AND THEIR VITAMERS | WATERS TECHNOLOGIES CORPORATION (US) | 2022-07-07 | — | — | WO | disclosed |
| EP-2773355-B1 | METHODS, FORMULATIONS, AND KITS FOR RAPIDLY REPLETING FOLATE LEVELS IN WOMEN | SOUTH ALABAMA MEDICAL SCIENCE FOUND (US) | 2022-06-08 | — | — | EP | disclosed |
| WO-2022109010-A1 | HEAVY CHAIN ANTIBODIES BINDING TO FOLATE RECEPTOR ALPHA | TENEOBIO, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220096408-A1 | COMPOSITIONS AND METHODS FOR TREATING HOMOCYSTINURIA AND OTHER CONDITIONS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2022-03-31 | — | — | US | disclosed |
| EP-3952857-A1 | COMPOSITIONS AND METHODS FOR TREATING HOMOCYSTINURIA AND OTHER CONDITIONS | The Regents Of The University Of Colorado (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130873-A1 | COMPOSITIONS AND METHODS FOR TREATING HOMOCYSTINURIA AND OTHER CONDITIONS | SLC6A12, CTH, SLC6A6 | MTHFD1 71/4885DHFR 614/4885SOST 3728/4885 |
| US-20240285683-A1 | Compositions And Methods For Enhancing Immunotherapy | RNASE1, DERA, SLC2A1 | MTHFD1 45/4885DHFR 199/4885SOST 4213/4885 |
| US-20260114488-A1 | COMPOSITIONS AND METHODS FOR PROMOTING DEVELOPMENT OF INFANT | SLC19A1, MTHFD1, MTHFD2 | MTHFD1 2/4885DHFR 18/4885SOST 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.